The Spectrum of Thiazolidinediones Against Respiratory Tract Pathogenic Bacteria: An In-Vitro and In-Silico Approach.

CONCLUSION: DTZD12 and DTZD16 can be developed into antibacterial drugs for respiratory tract infections to oppose bacterial resistance, or can also be used as leads for repurposing the existing 2,4-thiazolidinediones. PMID: 32552647 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32552647?dopt=Abstract

Source: Current Pharmaceutical Biotechnology - June 17, 2020 Category: Biotechnology Authors: Al Bratty M, Hakami AQ, Masmali HA, Alam MS, Alhazmi HA, Thangavel N, Najmi A, Moni SS, Haque A Tags: Curr Pharm Biotechnol Source Type: research